Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SOCMA Calls On Congress To Preserve TSCA
The Society of Chemical Manufacturers and Affiliates (SOCMA) has called on Congress to update the Toxic Substances Control Act (TSCA) chemical management regulation, without enacting a complete overhaul.
The Society of Chemical Manufacturers and Affiliates (SOCMA) has called on Congress to update the Toxic Substances Control Act (TSCA) chemical management regulation, without enacting a complete overhaul.
Oramed Pharmaceuticals has received a government grant of NIS3.1 million from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel.
Synta Pharmaceuticals has reported a net loss of $8.5 million, or $0.25 per basic and diluted share, for the second quarter in 2009, as compared to a net
GlaxoSmithKline (GSK) confirmed on 22nd July that it had contracts to supply 195 million doses of its pandemic (H1N1) 2009 adjuvanted influenza vaccine. It also had a variety
Bionovo has reported positive results from the phase 1B clinical trial of Bezielle (formerly BZL101), their lead drug candidate for advanced breast cancer. The primary objective of the
Napo Pharmaceuticals has completed the dose selection stage (Stage I) of the ADVENT trial of crofelemer, for the treatment of chronic diarrhea in people living with HIV/AIDS on
AlphaRx has entered into a collaboration agreement with Venturepharm to establish a drug development center in China Medical City, in China. It is expected to be used as
Eiger has acquired exclusive worldwide license to novel Hepatitis C Virus (HCV) technology from the Stanford University. The technology is focused on a variety of novel targets, including
Progenics Pharmaceuticals and Wyeth Pharmaceuticals, a division of Wyeth, have submitted a supplemental New Drug Application (sNDA) to FDA, and an Extension Application to EU. It is for
AstraZeneca and Astellas have entered into an agreement for the co-promotion of AstraZeneca’s Symbicort Turbuhaler (budesonide/formoterol, a dry powder inhaler), for the treatment of bronchial asthma in Japan.